

Special Issue

The 2nd Edition: Non-Specific Protection in the Response to Vaccination and Other Immune Stimulation

Message from the Guest Editors

Recent research has shown that vaccination, as well as microbial and non-microbial stimulation, can alter the immune system in a way that increases immune protection against unrelated pathogens. This is known as “non-specific effects”. Trained immunity is a functional state of the innate immune system that is characterized by long-term epigenetic and metabolic reprogramming of cells associated with potent immune responses. Trained immunity is dominantly mediated by myeloid cells, whereas adaptive immune memory is a unique characteristic of lymphocytes, mainly T cells and B cells. This Special Issue welcomes all original studies and reviews related to NSE and trained immunity in humans and animal models. We encourage you to submit your research.

Guest Editors

Dr. François Meurens

Swine and Poultry Infectious Diseases Research Center (CRIPA),
Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe,
QC J2S 2M2, Canada

Dr. Fanny Renois

BIOEPAR, INRAE, Oniris, 44307 Nantes, France

Prof. Dr. Jianzhong Zhu

College Veterinary Medicine, Yangzhou University, Yangzhou 225009,
China

Deadline for manuscript submissions

31 August 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/192371

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).